Testing is available for metastatic HR+ HER2- breast cancer using our Oncopanel multigene NGS panel.
Predictive Testing
The Oncopanel assay can detect mutations in a variety of predictive genes:
- AKT1 and PTEN: Predict response to Capivasertib
- BRCA1 and BRCA2: Predict response to PARP inhibitor therapy
- ESR1: Predict response to Elacestrant
- PIK3CA: Predict response to PIK3CA inhibitors
In addition, the Oncopanel assay can detect mutations in genes associated with inherited breast cancer predisposition, in which case follow-up germline/hereditary testing is recommended (see below).
Hereditary Testing
Hereditary testing is available for patients with mutations associated with inherited breast cancer predisposition, (see our Hereditary Cancer page for details).